Psychedelics & Cannabis

Atypical psychedelics such as ketamine, MDMA, and ibogaine show fast-acting promise for depression, PTSD, and addiction beyond 5-HT2A.

Learn how the inhibition constant and 5-HT2A binding explain LSD effects—and why potent atypical antipsychotics may rapidly end a bad trip.

FDA hearing spotlights debates over psychedelic therapy: who administers, how to prove efficacy, and how to track safety as approvals near.

Single-dose DT120 ODT delivers rapid, sustained anxiety relief in phase 3 GAD trial, supporting FDA breakthrough path and NDA plans.

Health Canada has authorized a 200-participant phase 2 trial testing a single psilocybin dose for major depressive disorder, with dosing set to begin in 2027.

Psychedelic psilocybin therapy shows year-long relief in treatment-resistant depression, with strong response rates and stable safety.

FDA boosts DT120 lysergide ODT after phase 3 shows lasting depression relief; psychedelic tablet also advances for anxiety and other brain disorders.

New trial shows edible THC worsens lane control and reaction time at low blood levels, raising doubts about current legal impairment limits.

Clearmind patents MDMA plus PEA combo aiming to boost PTSD, anxiety and eating-disorder therapy as FDA issues new psychedelic trial guidance.

PleoPharma secures $6.5M NIDA grant to advance phase 3 PP-01 trial, aiming to ease cannabis withdrawal and address untreated cannabis use disorder.

DT120 (lysergide) hits all endpoints in phase 3 GAD trial, cutting anxiety scores with a single dose.

From long-acting antipsychotics to psilocybin and new ADHD meds, clinicians weigh emerging therapies reshaping depression and postpartum care.

New analysis shows COMP360 psilocybin sessions for PTSD stay mostly silent, with nondirective support boosting safety and autonomy.

COMP360 psilocybin shows rapid, durable gains in treatment‑resistant depression, as psychedelics continue to grow.

How shifting cannabis laws shape potency, access, and risk—revealing why anxiety, paranoia, and psychosis can surge when users cross regulatory borders.

New Delphi consensus guides off-label IV ketamine for depression, detailing protocols and rapid antisuicidal mechanisms via neuroplasticity and BDNF.

PP-01 targets CB-1 recovery and dopamine balance, aiming to ease cannabis withdrawal and boost abstinence as a fast-tracked phase 3 trial advances.

New data in cannabis use disorder show investigational drug PP-01 cuts irritability 42% in trials.

Phase 3 data show COMP360 psilocybin delivers rapid, lasting relief in treatment-resistant depression; FDA filing advances toward 2027 launch.

Phase 3 results show single-dose DT120 lysergide ODT delivers rapid, lasting relief in major depressive disorder with mild, transient adverse effects.

MAPS probes psychedelic-assisted healing for formerly incarcerated people, spotlighting trauma, access barriers, and a public-health policy path.

AbbVie’s short-acting psychedelic bretisilocin shows rapid MADRS drops in phase 2a MDD trials, hinting at scalable, supervised depression care.

Yale psychiatrists test esketamine vs IV ketamine for resistant depression, probing long-term safety, side effects, and misuse in real-world care.

New evidence shows CBT timed after ketamine boosts lasting depression relief; Yale tests digital therapy Rejoyn to scale the neuroplasticity window.

Review the highlights from last week's meeting of the American Society for Clinical Psychopharmacology.